Abbott India
- Market cap
- ₹ 53,249 Cr.
- P/E
- 34.6x
- P/B
- 11.29x
- 52-week range
- 24,650 – 30,655
- ROE
- 34%
- ROCE
- 45%
- Dividend yield
- 2.1%
- Debt / equity
- 0.04
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Abbott India Limited is an India-based pharmaceutical company. The Company is involved in product development, manufacturing, sales, and customer service. It distributes products and solutions in multiple therapeutic categories, such as women's health, gastroenterology, cardiology, metabolic disorders and primary care. It operates in a single reportable business segment, which is Pharmaceuticals. The Company’s products include Arachitol Nano, Digeraft, Influvac, Colospa, Duphalac, Librax, Creon, Duphaston, Prothiaden, Cremaffin, Duvadilan, Thyronorm, Cremaffin Plus, Ganaton, Udiliv, Digene, Heptral, Vertin, Zolfresh, Citrosoda UTI, Digene Insta On The Go, Digeraft tablet, Duphaston OD, Pneumoshield 14, Prothiaden Neu, Vonefi, Levesam, and LOBATE M Skin Cream, among others. The Company sells its products through independent distributors primarily within India.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Abbott India against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)34.6 against a typical 34: pricier than most peers (1st = cheapest).113th of 220
- Sales growth+4.4% against a typical +15.6% from a year earlier.137th of 197
- Profit growth+17.2% against a typical +18.9% from a year earlier.85th of 160
- Share price, 3 months−4.9% against a typical −0.5%.124th of 200
- Size₹ 53,249.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).12th of 199
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,494 | 1,437 | 1,439 | 1,558 | 1,633 | 1,614 | 1,605 | 1,738 | 1,757 | 1,724 | 1,710 | 1,814 |
| Expenses | 1,113 | 1,049 | 1,109 | 1,167 | 1,194 | 1,178 | 1,176 | 1,293 | 1,255 | 1,261 | 1,229 | 1,291 |
| Operating Profit | 381 | 388 | 330 | 391 | 439 | 436 | 429 | 446 | 502 | 463 | 481 | 522 |
| OPM % | 25% | 27% | 23% | 25% | 27% | 27% | 27% | 26% | 29% | 27% | 28% | 29% |
| Other Income | 56 | 56 | 81 | 67 | 60 | 72 | 76 | 73 | 70 | 70 | 76 | 75 |
| Interest | 3 | 3 | 3 | 3 | 2 | 2 | 4 | 6 | 8 | 5 | 6 | 6 |
| Depreciation | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 19 | 19 | 19 | 19 | 20 |
| Profit before tax | 415 | 422 | 390 | 437 | 479 | 488 | 483 | 493 | 546 | 509 | 531 | 572 |
| Tax % | 25% | 26% | 26% | 25% | 25% | 26% | 24% | 26% | 24% | 26% | 26% | 25% |
| Net Profit | 313 | 311 | 287 | 328 | 359 | 361 | 367 | 366 | 415 | 376 | 395 | 429 |
| EPS in Rs | 147.27 | 146.35 | 135.09 | 154.36 | 168.76 | 169.78 | 172.73 | 172.18 | 195.43 | 176.93 | 185.86 | 201.66 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 10%
- 5 Years
- 10%
- 3 Years
- 9%
- TTM
- 6%
- 10 Years
- 20%
- 5 Years
- 17%
- 3 Years
- 18%
- TTM
- 11%
- 10 Years
- 19%
- 5 Years
- 7%
- 3 Years
- 4%
- TTM
- —
- 10 Years
- 31%
- 5 Years
- 34%
- 3 Years
- 35%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Abbott India | ₹ 26,390.00 | ₹ 53,249 Cr. | 34.6x | 11.3x | 34% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Maithilee Mistry
- Chief Financial Officer
- Sangeeta Mukesh Shetty
- Compliance Officer, Company Secretary, Associate Director - Secretarial
- Kartik Rajendran
- Managing Director, Executive Director
- Rajan Kalantre
- Director - Business Human Resources
- Jejoe Karankumar
- Director - Medical Affairs
- Anushree Kunhambu
- Associate Director - New Product Introduction and Therapy Area Strategy
- Amol Metkar
- Plant Director, Goa
- Richa Tripathi
- Associate Director - Sales Force Effectiveness, Project Management Office
Prices are delayed and for information only. Nothing on this page is investment advice.